4 Stocks to Watch on Tuesday: AMGN, BBY and More
Amgen Shares Are Trading Lower Following the Results of Its Phase 2 Study With MariTide in Obesity.
Amgen Announced Data At 52 Weeks In Phase 2 Study With MariTide (Maridebart Cafraglutide, Formerly AMG 133) Subcutaneously Administered Monthly Or Less Frequently, Showing Up To ~20% Average Weight Loss At Week 52 Without A Weight Loss Plateau
Gilead Acquires Investigational HIV Vaccine From Spanish Biotech Aelix
(PFE) - Analyzing Pfizer's Short Interest
S&P 500, Dow Hit Records Right After Open | Live Stock
loading...